Corporate & Investor Presentation

Track record of strong financial returns for shareholders $1.7 Revenue ($B) 12% CAGR $3.1 LTM 2Q16 LTM 2Q21 Non-GAAP Operating Income ($M) 17% CAGR $436 $973 LTM 2Q16 LTM 2Q21 Non-GAAP EPS 15% CAGR $5.30 $2.64 LTM 2Q16 LTM 2Q21 Total shareholder return, TSR (NYSE shares as of 12/31/2020): 1-yr 38% NOTE: See reconciliation to GAAP in Appendix | 3-yr 160% | 5-yr 327% 33 © 2021 ResMed | Corporate & Investor Presentation - updated 28JAN21 ResMed

View entire presentation